Harvard profs maintain that the FDA's recent actions on Covid-19 devalue the gold standard and threaten public trust
The FDA’s decision to provide an emergency use authorization for a pair of suspect malaria drugs threatens to derail the US’ well-known gold standard for drug evaluations while eroding the public’s respect for the agency — essential for maintaining confidence in the efficacy and safety of therapies put on the market.
That’s the bottom line from a pair of Harvard professors — Benjamin Rome and Jerry Avorn, a frequent FDA critic — who tackled the FDA in an op-ed for its recent work on Covid-19 drugs in the pages of the New England Journal of Medicine.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,600+ biopharma pros reading Endpoints daily — and it's free.